Who Founded Novartis AG?

The origin of Novartis AG is not a single founding moment but a complex collision of two 19th-century Swiss chemical companies that were forced together by the brutal economics of the modern pharmaceutical industry. The story begins in 1859 when Alexander Clavel and Alfred Kern founded a chemical dye works in Basel, Switzerland, to produce fuchsine, a synthetic red dye used in the textile industry. This company, which later became known as Ciba, eventually realized that the chemical compounds used to dye fabrics also had biological effects, leading to the discovery of the first synthetic antiseptic in the 1890s. Simultaneously, in 1886, Edouard Naville founded Sandoz in Basel to manufacture tartaric acid, a chemical used in medicine. Sandoz soon began producing synthetic pharmaceuticals, including the first synthetic antipyrine for fever reduction. For over a century, Ciba and Sandoz operated as fierce competitors, both growing into massive chemical and pharmaceutical conglomerates through internal discovery and aggressive acquisitions. However, by the early 1990s, both companies were facing a crisis. The cost of developing new drugs had skyrocketed, the Swiss Franc was strong, making exports expensive, and the global pharmaceutical industry was undergoing a wave of massive consolidations. In 1996, the boards of Ciba-Geigy and Sandoz made the radical decision to merge their pharmaceutical and agrochemical businesses into a single entity, creating Novartis, a name derived from the Latin word for 'new beginning.' The merger was valued at approximately $30 billion and was billed as a merger of equals, but the reality was a desperate attempt to achieve the scale necessary to survive in the new era of blockbuster drug development. The integration was notoriously difficult. The two companies had vastly different corporate cultures: Ciba was known for its aggressive, sales-driven approach, while Sandoz was more research-oriented and conservative. The new management team, led by Daniel Vasella, immediately faced the task of cutting thousands of jobs, closing redundant R&D facilities, and rationalizing a product portfolio that had massive overlap. The early years of Novartis were marked by constant restructuring and a series of high-profile acquisitions designed to fill pipeline gaps, including the purchase of Chiron Corporation in 2006 for $5.1 billion. It was not until the appointment of Joe Jimenez as CEO in 2010 that the company began to find its strategic footing, focusing on innovative medicines, generics through Sandoz, and eye care through Alcon. However, the conglomerate structure eventually became a burden, masking the true growth rate of the innovative pipeline and depressing the company's valuation multiples. This led to the final, defining chapter of the origin story: the decision by Vas Narasimhan to spin off Sandoz in 2023, effectively completing the transformation from a 19th-century chemical dye works to a 21st-century pure-play innovative medicines powerhouse.